This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.

An object is to provide a therapeutic agent for a malignant mesothelioma and a method for selecting a patient having a malignant mesothelioma having a high expression level of oxytocin receptors. The object can be achieved by a therapeutic agent for a malignant mesothelioma, the therapeutic agent including, as an active ingredient, a compound that targets an oxytocin receptor.

The present invention relates to biomarkers that are associated with joint disorders, and methods of using the biomarkers diagnose joint ailments, monitor the progression of joint ailments, determine when treatments is indicated, and monitor the efficiency of treatment. Also provided are methods for treating joint ailments, which comprise administering chelated trace minerals to animals diagnosed with or predisposed to having joint ailments.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

The present invention relates to biomarkers that are associated with joint disorders, and methods of using the biomarkers diagnose joint ailments, monitor the progression of joint ailments, determine when treatments is indicated, and monitor the efficiency of treatment. Also provided are methods for treating joint ailments, which comprise administering chelated trace minerals to animals diagnosed with or predisposed to having joint ailments.

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female.

Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based on ratios of steroids in samples obtained from the pregnant female. Further, the methods can include treating the pregnant female identified susceptible to spontaneous preterm delivery.

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

The application is about a method for diagnosing autism spectrum disorder (ASD) in a human subject, comprising providing a device comprising a reagent for determining the concentration of arginine vasopressin (AVP) in a biological sample from the subject; and measuring the concentration of AVP in the sample using the device. Disclosed is also a method for diagnosing ASD, comprising providing a first device comprising a reagent for determining a concentration of AVP and a second device comprising a reagent for determining a concentration of one or more analytes selected from arginine vasopressin receptor 1a and oxytocin receptor, to determine the concentrations of AVP and of the one or more analytes. Disclosed is also a method of predicting severity of ASD in a male human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in a biological sample from the subject using the device. Disclosed is also a method of predicting likelihood of an ASD in a human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in cerebrospinal fluid using the device.